Predictions

The FDA will approve Merck's HYPERION-based label expansion for Winrevair (sotatercept) in newly diagnosed PAH patients by September 28, 2026.

HYPERION was stopped early for overwhelming efficacy (76% reduction in clinical worsening, HR 0.24) and this is the second sotatercept label expansion in under a year after the ZENITH-based update was approved cleanly in October 2025, establishing a clear precedent pathway for this exact regulatory ask. Supplemental label expansions for an already-approved, well-characterized biologic with this strength of confirmatory data carry very low CRL risk. [cor: unreachable] [hyp: used:0 (candidates ret

The FDA will approve Ionis/GSK's zilganersen for Alexander disease by its September 22, 2026 PDUFA date.

Zilganersen is a first-in-class ASO for the ultra-rare, fatal Alexander disease, with a clean, statistically significant pivotal readout (33.3% LS-mean gait-speed improvement at Week 61) and a concordant GFAP biomarker signal, plus Breakthrough Therapy and Priority Review. Cornelius's first-in-class ceiling logic (45-55% absent class precedent) argues for caution despite the clean data, so I lean only modestly above that band. No relevant store hypotheses found (top similarity 0.31, all off-subj

Henry Hub spot price will close between $2.90 and $3.05/MMBtu on Sep 8, 2026

HH has been pinned at $2.98 (8-week high) for multiple consecutive sessions per the story log, and hyp_865d78de5b27 confirms a tighter supply-demand balance constraining swings. A +-2.5% band around a price that has shown limited single-day movement recently is a comparatively high-probability outcome, though Cornelius warns of ±30% single-day summer swings as a tail risk. [cal: raw 0.55 -> 0.80, +25pp level]

US spot Bitcoin ETFs post a net outflow day on Sep15, 2026

Confirmed $463M net outflow across Sep8-11 and a BTC pullback to $76,874 from the recent $81K+ highs are consistent with continued redemption pressure into the FOMC, where broader risk-off dampens crypto flows. Weighed a hypothesis about BlackRock's ETH staking ETF inflows providing an institutional demand floor -- a different product but a mild reminder that crypto ETF flows aren't uniformly negative right now, tempering the estimate slightly below the raw trend-continuation read. [cal: raw 0.5

Gold (spot XAU/USD) closes below $4,300/oz on Tuesday Sep15, 2026

Gold already traded below $4,300 intraday Monday evening ($4,322.60 as of 10:28pm EDT, with same-day headlines citing a drop below $4,300), continuing its pullback from the Jan 2026 high amid a hawkish-Fed-dominates-oil-shock dynamic. Weighed hypotheses: the $4,310-4,327 zone is a genuine balance point between safe-haven and inflation-hedge bids (path-dependent), Fed officials' lack of dovish signaling caps upside above $4,400, and Gulf SWF physical demand is a modest under-recognized support fa

Gold (spot XAU/USD) closes below $4,280.00/oz on September 15, 2026

Gold spot ~$4,310-4,319 currently, roughly 1% above this threshold. Cornelius's calibration is unambiguous that rate-shock (hawkish FOMC pricing, 10Y near 5%) beats oil-driven safe-haven demand near-term for gold, but the fresh oil supply shock is a genuine offsetting force this cycle specifically. A gold-equilibrium-at-current-levels hypothesis (0.58 sim) argues the current price already reflects both forces in balance, keeping this near a coin flip with a slight bearish lean from the rate-shoc

Brent crude closes above $107/bbl on Tuesday Sep15, 2026

Brent traded $109.44-109.80 Monday after Saudi Arabia's East-West pipeline (7mbd, 30-40% of Gulf export capacity) was shut following drone strikes with no public repair timeline -- Cornelius classifies this as a durable physical-disruption premium, not a fear spike, giving it more staying power. Notably, the store's long-standing hypothesis that 'Saudi oil infrastructure is intact, not under imminent threat' (Brier 0.091, 100% confidence, 6 uses) is now explicitly falsified by this week's strike

Ethereum (ETH/USD) closes below $2,480 on September 15, 2026 (UTC day)

ETH quoted $2,475-2,520 through Sep14, straddling this threshold. Cornelius flags ETH's 1.3-1.5x beta to BTC in risk-off conditions, and with BTC leaning bearish this cycle, ETH should underperform on a relative basis, though the tight proximity to the threshold keeps this close to a coin flip. An ETH-ETF-structural-floor-near-$1,650 hypothesis (0.61 sim) is now stale (price level far below current) and was not weighted meaningfully. [cal: raw 0.54 -> 0.54, +0pp level]

Bitcoin (BTC/USD) closes below $77,000 on September 15, 2026 (UTC day)

BTC traded $77,100-77,873 through Sep14, continuing its multi-week downtrend (13% YTD) with the current print sitting just above this threshold. Cornelius models exogenous (not endogenous) fear here -- rate-shock plus AI-sector contagion -- and recommends a 55-60% bearish lean for BTC below current levels pre-FOMC; explicitly cautioned against the contrarian extreme-fear-is-bullish read since this is exogenous macro risk-off. A BTC-recent-high-near-$79,500 hypothesis (0.55 sim) reinforces the do

Phase 3 TROPION-Breast02 trial data (datopotamab deruxtecan in first-line metastatic triple-negative breast cancer) will be presented at ESMO 2026 congress (September 18-22, 2026)

ESMO 2026 abstract deadline was May 12 (regular) and Sept 8 (late-breaking). TROPION-Breast02 is listed as a key expected presentation at ESMO 2026. However, Cornelius warns that conference anchoring without explicit abstract confirmation yields 35-50%. AstraZeneca/Daiichi have strong incentive to present at the largest oncology congress. No confirmed abstract submission found in search. Set at 0.45 — midpoint of the conference-anchor uncertainty range, with slight upward tilt given this is a sp

ESMO 2026 Congress (September 18-22, Barcelona) will feature at least 2 Phase 3 ADC trial readouts showing statistically significant improvement in primary endpoint vs. standard of care

ESMO 2026 (September 18-22, Barcelona) is the premier European oncology conference. Antibody-drug conjugates (ADCs) are the most active drug class in oncology 2025-2026. Multiple Phase 3 trials maturing: T-DXd (DESTINY-Breast updates, gastric, lung), sacituzumab govitecan, disitamab vedotin, PTK7-ADCs, and others. Historical precedent: ESMO has featured major ADC data every year 2022-2025. Pipeline data from ASCO 2026 suggests multiple Phase 3 ADC readouts maturing. P(≥2 positive Phase 3 readout

AstraZeneca TROPION-Lung08 (datopotamab deruxtecan vs docetaxel) will demonstrate statistically significant OS benefit at ESMO 2026 (September 18-22, Barcelona)

TROPION-Lung08 tests dato-DXd vs docetaxel in pretreated NSCLC. OS data at ESMO 2026 is within the plausible readout window given trial timeline. However, prior TROPION-Lung01 missed OS significance despite PFS improvement—an unfavorable precedent for the dato-DXd mechanism in lung cancer. TROPION-Lung08 may have more selected population. Stories.yaml previously tracked this at p=0.40; calibration notes suggest modest downward correction for ADC OS prediction. P = 0.38.

At least one antibody-drug conjugate (ADC) Phase 3 trial will report statistically significant overall survival benefit in lung cancer at ESMO 2026 (September 18-22)

ESMO 2026 (September 18-22, Barcelona) is the premier European oncology congress. ADCs are the leading oncology drug class in 2026 with multiple Phase 3 NSCLC trials ongoing. Beyond TROPION-Lung08, other ADC programs in lung cancer include patritumab deruxtecan (HER3-DXd), telisotuzumab vedotin, and others. At least one of these programs demonstrating OS benefit at ESMO is consistent with the pace of ADC readouts in 2025-2026. Late-breaking abstract deadline is September 8, giving confidence tha

FDA's publicly posted briefing documents for the Sep 23, 2026 GRAIL Galleri PMA advisory committee meeting (expected ~Sep 21) will include an unfavorable or cautionary staff assessment of the application (e.g. flagging immature overall-survival data or false-positive/overdiagnosis concerns).

This is the first-ever FDA AdCom for an MCED PMA with no mature OS data (only PATHFINDER 2 and NHS-Galleri year-1 results available), a genuinely contested review; FDA staff briefing documents for novel, high-scrutiny device categories frequently include cautionary language even when the ultimate panel vote is more favorable. fda|medium pattern-bias override applied instead of the general level shift. [cal: raw 0.65 -> 0.62, net -3pp fda|medium]

Zilganersen (Ionis Pharmaceuticals) receives FDA approval label covering patients ages 2 and older (not restricted to ages 5+) upon the September 22, 2026 PDUFA date

PDUFA Sep 22. Trial enrolled ages 5+ as primary population (10MWT p=0.041 at week 61) and 2-4 as supportive cohort (GMFM-88 motor improvement). Alexander disease is pediatric-onset and fatal; FDA favors inclusive pediatric labels when supportive data exists. P(approved)=0.55 (gen-90). P(ages 2+ in label | approved)≈0.60 — FDA may accept GMFM-88 supportive data or require supplemental study for youngest cohort. Compound: 0.55×0.60=0.33. Applied fda|medium correction: P=0.32.

Capricor Therapeutics announces Type A meeting request or resubmission plan for deramiocel within 30 days of Aug 22 PDUFA (by Sep 22 2026)

9-3 negative AdCom against deramiocel for DMD cardiomyopathy in July 2026; PDUFA Aug 22. P(CRL) ≈ 0.60 (consistent with gen-94 p=0.60). After CRL, companies typically request urgent Type A meeting (FDA responds within 30 days) to discuss path to resubmission. P(Capricor announces meeting request or resubmission plan by Sep 22 | CRL received Aug 22) = 0.75. P(announces | approval) ≈ 0 (no plan needed if approved). Total P = 0.60 × 0.75 = 0.45, rounded to 0.40 applying mild drug-approvals calibrat

FDA approves AQNEURSA (levacetylleucine) for ataxia-telangiectasia by September 22, 2026

Phase III IB1001-303 met primary and all key secondary endpoints with high statistical significance. First-ever approved A-T treatment; extreme unmet need. Priority Review, PDUFA Sep 19. Prior approval as sNDA (Niemann-Pick NPC). Drug-approvals is strongest calibration domain (Brier 0.157). P=0.55 reflects high confidence tempered by inherent uncertainty in rare-disease first-approvals.

Ionis Pharmaceuticals receives a Rare Pediatric Disease Priority Review Voucher (RPD PRV) from FDA upon zilganersen approval at Sep 22 PDUFA date

Alexander disease (AxD) is a rare progressive pediatric neurological disease. RPD PRV eligibility requires: (1) rare pediatric disease designation, (2) BLA/NDA approval, (3) PRV program active (Congress reauthorized through FY2027). Compound: P(zilganersen approved by Sep 22) x P(PRV | approved). Prior gen-137 prediction: P(approved) = 0.50. P(RPD PRV | approved) depends on RPD designation; AxD is a qualifying pediatric rare disease. PRV program historically grants voucher on ~80% of qualifying

FDA approval of zilganersen (if granted) by Sep 22, 2026 includes issuance of a Rare Pediatric Disease Priority Review Voucher

Zilganersen holds a confirmed Rare Pediatric Disease designation, which normally converts to a transferable PRV upon approval. However, the RPD voucher program's reauthorization has been entangled in a Senate legislative fight per recent BioSpace coverage, adding procedural uncertainty to voucher issuance timing even if the drug itself is approved. Compound estimate: P(approval)~0.78 x P(PRV issued given approval, accounting for program disruption risk)~0.77. [cal: raw 0.60 -> 0.60, +0pp level]

Zilganersen is granted a Rare Pediatric Disease Priority Review Voucher concurrent with FDA approval by Sep 22, 2026

Contingent on zilganersen's approval (~0.75, see companion prediction) and Rare Pediatric Disease designation converting to a Priority Review Voucher upon approval, which is close to automatic under the current statute absent a program lapse -- joint probability lands around 0.64 before calibration adjustment. [cal: raw 0.64 → 0.53, net -11pp fda|medium]